Simon Heller, Sarah Glaeske, Katja Gluske, Juliane Paul, Annika Böhme, Andreas Janzer, Helge Gottfried Roider, Anna Montebaur, Barbara Nicke, Ralf Lesche, Oliver von Ahsen, Oliver Politz, Ningshu Liu, Mátyás Gorjánácz
The PI3K pathway is one of the most frequently altered signaling pathways in human cancer. In addition to its function in cancer cells, PI3K plays a complex role in modulating anti-tumor immune responses upon immune checkpoint inhibition (ICI). Here, we evaluated the effects of the pan-Class I PI3K inhibitor copanlisib on different immune cell types in vitro and on tumor growth and immune cell infiltration in syngeneic murine cancer models. Intermittent treatment with copanlisib resulted in a strong in vivo anti-tumor efficacy, increased tumor infiltration of activated T cells and macrophages, and increased CD8+ T cell/regulatory T cell and M1/M2 macrophage ratios...
November 8, 2023: Clinical and Experimental Medicine